Tag: molecular diagnostics for sexually transmitted diseases market research

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Molecular Diagnostics For Sexually Transmitted Diseases Market CAGR Outlook And Future Development

The market size for molecular diagnostics related to sexually transmitted diseases has experienced rapid growth in recent years. It is projected to expand from $3.67 billion in 2025 to $4.07 billion in 2026, at a compound annual growth rate (CAGR) of 10.7%. This growth observed in the historical period can be attributed to factors such as the reliance on conventional serological tests, the limited availability of automated PCR systems, a lack of awareness regarding molecular diagnostics in emerging markets, the increasing prevalence of sexually transmitted infections, and manual, labor-intensive testing workflows.

The molecular diagnostics for sexually transmitted diseases market is projected to experience substantial expansion in the coming years. This market is set to reach $6.05 billion in 2030, showing a compound annual growth rate (CAGR) of 10.4%. This anticipated growth is linked to factors such as technological progress in automated PCR and nucleic acid extraction, the broadening availability of point-of-care molecular diagnostics, improvements in healthcare infrastructure within developing areas, the increasing implementation of laboratory information management systems (LIMS), and greater investment in research and development for quick and comprehensive diagnostic assays. Key trends during this period encompass the growing acceptance of nucleic acid-based testing approaches, the proliferation of point-of-care molecular diagnostic solutions, an escalating need for swift and precise STD detection, the merging of molecular diagnostics with laboratory information systems, and the development of automated PCR and high-throughput diagnostic platforms.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=81498837&type=smp&name=Molecular%20Diagnostics%20For%20Sexually%20Transmitted%20Diseases%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Sep_PR

Molecular Diagnostics For Sexually Transmitted Diseases Market Growth Drivers: What’s Behind The Acceleration?

The increasing incidence of sexually transmitted infections is anticipated to drive forward the expansion of the molecular diagnostics for sexually transmitted diseases market. Sexually transmitted infections (STIs) are defined as ailments resulting from bacteria, viruses, or parasites spread via sexual interaction, impacting both the reproductive and urinary systems. The rise in STIs is predominantly attributed to the inconsistent application of protective measures. Such insufficient protection contributes to the simpler spread of these infections among sexually active populations. Molecular diagnostic methods for sexually transmitted infections (STIs) are crucial for managing these conditions, as they allow for the precise and early identification of pathogens, even in those without symptoms, thereby enabling prompt treatment, decreasing disease spread, and enhancing overall results for patients. As an illustration, data from June 2024 released by the UK Health Security Agency (UKHSA), a UK-based government agency, showed that England recorded 401,800 new STI diagnoses in 2023, representing a 4.7% rise from the 383,789 cases documented in 2022. Consequently, the escalating prevalence of sexually transmitted infections is fueling the expansion of the molecular diagnostics for sexually transmitted diseases market.

Molecular Diagnostics For Sexually Transmitted Diseases Market Segmentation And Category Overview

The molecular diagnostics for sexually transmitted diseases market covered in this report is segmented –

1) By Product: Instruments And Services, Consumables, Software

2) By Technology: Laboratory Testing, Point-Of-Care Testing

3) By Application: Chlamydia Trachomatis (CT) Or Neisseria Gonorrhoeae (NG) Testing, Syphilis Testing, Gonorrhea Testing, Herpes Simplex Virus (HSV) Testing, Human Papillomavirus (HPV) Testing, Human Immunodeficiency Virus (HIV) Testing, Trichomonas, Ureaplasma And Mycoplasma, Other Applications

Subsegments:

1) By Instruments And Services: Molecular Diagnostic Analyzers, Automated Polymerase Chain Reaction Systems, Nucleic Acid Extraction Instruments, Diagnostic Service Providers, Maintenance And Calibration Services, Installation And Training Services

2) By Consumables: Deoxyribonucleic Acid Extraction Kits, Ribonucleic Acid Extraction Kits, Polymerase Chain Reaction Reagents, Nucleic Acid Probes, Control And Reference Standards, Detection Enzymes And Buffers

3) By Software: Data Interpretation And Reporting Software, Polymerase Chain Reaction Workflow Management Software, Laboratory Information Management Systems, Diagnostic Decision Support Software, Quality Control Monitoring Software

Molecular Diagnostics For Sexually Transmitted Diseases Market Trends: What’s Defining The Industry’s Next Phase?

Leading companies in the molecular diagnostics for sexually transmitted diseases market are concentrating on developing innovative solutions, such as rapid point-of-care polymerase chain reaction (PCR) devices, to enhance diagnostic speed, accuracy, and accessibility. These rapid point-of-care PCR devices are portable molecular diagnostic tools that integrate sample preparation, amplification, and detection into a single, compact unit, enabling timely and highly sensitive pathogen detection outside traditional laboratory settings. For instance, in March 2025, Visby Medical, a US-based diagnostic technology company, introduced the Visby Medical Women’s Sexual Health Test. This product is a single-use, handheld PCR device designed to identify chlamydia, gonorrhea, and trichomoniasis from vaginal samples within 30 minutes. It operates without requiring external instrumentation or cold-chain logistics, features an integrated amplification system, and provides lab-quality results directly at the point of care to support immediate clinical decisions. The test is authorized for prescription home use, making it the first U.S. Food and Drug Administration (FDA)-cleared molecular diagnostic test for multiple sexually transmitted infections (STIs) that can be utilized beyond clinical settings. This launch signifies a shift toward decentralized diagnostic solutions that broaden accessibility, especially for underserved or remote populations.

Molecular Diagnostics For Sexually Transmitted Diseases Market Key Participants And Competitive Landscape

Major companies operating in the molecular diagnostics for sexually transmitted diseases market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Hologic Inc., bioMérieux S.A., QuidelOrtho Corporation, QIAGEN N.V., Cepheid, Sansure Biotech Inc., OraSure Technologies Inc., Meridian Bioscience, Seegene Inc., Visby Medical Inc., Zeesan Biotech, Binx Health Inc., GCC Biotech, GeneProof, Solone Life Sciences India (P) Ltd.

View The Full Molecular Diagnostics For Sexually Transmitted Diseases Market Report:

https://thebusinessresearchcompany.com/report/molecular-diagnostics-for-sexually-transmitted-diseases-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Sep_PR

Molecular Diagnostics For Sexually Transmitted Diseases Market Geographic Analysis: Where Is Demand Rising Fastest?

North America was the largest region in the molecular diagnostics for sexually transmitted diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molecular diagnostics for sexually transmitted diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

The molecular diagnostics sector for sexually transmitted diseases (STDs) has seen significant momentum recently, driven by advances in technology and rising infection rates. As diagnostic tools become more sophisticated and accessible, the market is poised for substantial growth in the coming years. Let’s explore the current market size, key growth drivers, segmentation, innovations, and regional insights shaping this vital healthcare field.

Current Market Size and Growth Outlook for Molecular Diagnostics in STDs

The molecular diagnostics market for sexually transmitted diseases has expanded quickly in recent years. It is projected to grow from $3.67 billion in 2025 to $4.07 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.7%. Past growth was largely driven by dependence on traditional serological tests, limited access to automated PCR systems, lack of awareness about molecular diagnostics in emerging economies, rising incidence of STDs, and labor-intensive manual testing workflows.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27351&type=smp

Looking ahead, the market is expected to surge to $6.05 billion by 2030, maintaining a CAGR of 10.4%. This anticipated expansion is attributed to advancements in automated PCR and nucleic acid extraction technologies, growth of point-of-care molecular diagnostic solutions, improved healthcare infrastructure in developing countries, broader adoption of laboratory information management systems (LIMS), and increased research and development investment in rapid and multiplex diagnostic assays. Leading trends forecasted include rising use of nucleic acid-based testing techniques, expansion of point-of-care diagnostics, demand for fast and accurate STD detection, integration with laboratory information systems, and the growth of automated high-throughput PCR platforms.

Increasing Prevalence of STDs Boosting Market Demand

The growing number of sexually transmitted infections worldwide is a significant factor driving the molecular diagnostics market. STDs, caused by bacteria, viruses, and parasites transmitted primarily through sexual contact, affect the reproductive and urinary systems. The rise in infections is mainly due to inconsistent use of protection methods during sexual activity, which facilitates easier disease transmission.

Access The Complete Molecular Diagnostics For Sexually Transmitted Diseases Market Report:

https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-for-sexually-transmitted-diseases-global-market-report

Molecular diagnostics play a crucial role in controlling these infections by enabling early, precise detection of pathogens—even in individuals without symptoms. This leads to timely treatment, reduced spread of infections, and improved patient outcomes. For example, in June 2024, the UK Health Security Agency (UKHSA) reported 401,800 new STI cases in England for 2023, a 4.7% increase from 383,789 cases in 2022. This upward trend in STD prevalence is a key driver for expanding molecular diagnostic solutions.

Market Segmentation and Revenue Sources in Molecular Diagnostics for STDs

The molecular diagnostics market for sexually transmitted diseases is segmented into several categories for detailed analysis:

1) By Product: Instruments and Services, Consumables, and Software

2) By Technology: Laboratory Testing and Point-of-Care Testing

3) By Application: Testing for Chlamydia Trachomatis (CT) or Neisseria Gonorrhoeae (NG), Syphilis, Gonorrhea, Herpes Simplex Virus (HSV), Human Papillomavirus (HPV), Human Immunodeficiency Virus (HIV), Trichomonas, Ureaplasma and Mycoplasma, and other infections.

Further breakdown includes:

– Instruments and Services such as molecular diagnostic analyzers, automated PCR systems, nucleic acid extraction instruments, diagnostic service providers, maintenance and calibration, and installation/training services.

– Consumables comprising DNA and RNA extraction kits, PCR reagents, nucleic acid probes, control and reference standards, detection enzymes, and buffers.

– Software offerings include data interpretation and reporting software, PCR workflow management, laboratory information management systems, diagnostic decision support, and quality control monitoring software.

Innovative Technologies Driving Transformation in Molecular Diagnostics

Leading companies in this sector are focusing on innovative solutions like rapid point-of-care PCR devices that enhance diagnostic speed, accuracy, and accessibility. These portable tools combine sample preparation, amplification, and detection in a single unit, allowing for fast, sensitive pathogen identification outside traditional labs.

For instance, in March 2025, Visby Medical from the US introduced the Visby Medical Women’s Sexual Health Test, a single-use handheld PCR device capable of detecting chlamydia, gonorrhea, and trichomoniasis from vaginal samples within 30 minutes. This device operates without external instruments or cold-chain storage, includes integrated amplification, and delivers lab-quality results on-site to support immediate clinical decisions. It is authorized for prescription home use, making it the first FDA-cleared molecular diagnostic test for multiple STIs usable outside clinical environments. This highlights a shift toward decentralized diagnostics that improve access, especially in underserved or remote populations.

Key Players Shaping the Molecular Diagnostics for STDs Market

Several prominent companies are leading the molecular diagnostics market for sexually transmitted diseases, including:

F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Hologic Inc., bioMérieux S.A., QuidelOrtho Corporation, QIAGEN N.V., Cepheid, Sansure Biotech Inc., OraSure Technologies Inc., Meridian Bioscience, Seegene Inc., Visby Medical Inc., Zeesan Biotech, Binx Health Inc., GCC Biotech, GeneProof, and Solone Life Sciences India (P) Ltd.

Regional Market Leadership and Growth Forecast

In 2025, North America accounted for the largest share of the molecular diagnostics market for sexually transmitted diseases. Meanwhile, Asia-Pacific is projected to be the fastest-growing region during the forecast period. The analysis covers key regions including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, providing a broad perspective on global market dynamics.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Estimated Growth In Market Size Of The Molecular Diagnostics For Sexually Transmitted Diseases Market During 2026–2030?

The molecular diagnostics for sexually transmitted diseases market size has experienced rapid expansion in recent years. It is forecast to increase from $3.67 billion in 2025 to $4.07 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.7%. This historical growth can be attributed to several factors, including a reliance on conventional serological tests, the limited availability of automated PCR systems, low awareness of molecular diagnostics in emerging markets, the growing prevalence of sexually transmitted infections, and a manual, labor-intensive testing workflow.

The molecular diagnostics for sexually transmitted diseases market is anticipated to experience rapid expansion in the next few years, projected to reach $6.05 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.4%. This growth during the forecast period is fueled by technological progress in automated PCR and nucleic acid extraction, the wider availability of point-of-care molecular diagnostics, improvements in healthcare infrastructure in developing regions, increased adoption of laboratory information management systems (LIMS), and growing investment in research and development for rapid and multiplexed diagnostic assays. Significant trends expected during this period include the increasing use of nucleic acid-based testing methods, the expansion of point-of-care molecular diagnostic solutions, a rising demand for prompt and accurate STD detection, the integration of molecular diagnostics with laboratory information systems, and advancements in automated PCR and high-throughput diagnostic platforms.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27351&type=smp

Which Strategic Drivers Are Supporting The Molecular Diagnostics For Sexually Transmitted Diseases Market Development?

An increasing prevalence of sexually transmitted infections is projected to stimulate the growth of the molecular diagnostics for sexually transmitted diseases market moving forward. Sexually transmitted infections (STIs) are illnesses caused by bacteria, viruses, or parasites transferred through sexual contact, affecting the reproductive and urinary systems. The rising occurrence of sexually transmitted infections primarily stems from the inconsistent use of protection methods. This lack of protection allows for easier transmission of infections among sexually active individuals. Molecular diagnostics for sexually transmitted infections (STIs) are crucial in managing these infections by enabling early and accurate detection of pathogens, even in asymptomatic individuals, thereby facilitating timely treatment, reducing disease transmission, and improving overall patient outcomes. For instance, in June 2024, according to the UK Health Security Agency (UKHSA), a UK-based government agency, in 2023, there were 401,800 new STI diagnoses in England, marking a 4.7% increase compared to the 383,789 cases reported in 2022. Consequently, a rising prevalence of sexually transmitted infections is driving the growth of the molecular diagnostics for sexually transmitted diseases market.

What Segment Types Are Included In The Molecular Diagnostics For Sexually Transmitted Diseases Market Analysis?

The molecular diagnostics for sexually transmitted diseases market covered in this report is segmented –

1) By Product: Instruments And Services, Consumables, Software

2) By Technology: Laboratory Testing, Point-Of-Care Testing

3) By Application: Chlamydia Trachomatis (CT) Or Neisseria Gonorrhoeae (NG) Testing, Syphilis Testing, Gonorrhea Testing, Herpes Simplex Virus (HSV) Testing, Human Papillomavirus (HPV) Testing, Human Immunodeficiency Virus (HIV) Testing, Trichomonas, Ureaplasma And Mycoplasma, Other Applications

Subsegments:

1) By Instruments And Services: Molecular Diagnostic Analyzers, Automated Polymerase Chain Reaction Systems, Nucleic Acid Extraction Instruments, Diagnostic Service Providers, Maintenance And Calibration Services, Installation And Training Services

2) By Consumables: Deoxyribonucleic Acid Extraction Kits, Ribonucleic Acid Extraction Kits, Polymerase Chain Reaction Reagents, Nucleic Acid Probes, Control And Reference Standards, Detection Enzymes And Buffers

3) By Software: Data Interpretation And Reporting Software, Polymerase Chain Reaction Workflow Management Software, Laboratory Information Management Systems, Diagnostic Decision Support Software, Quality Control Monitoring Software

Which Trends Are Shaping The Molecular Diagnostics For Sexually Transmitted Diseases Market Landscape?

Major companies active in the molecular diagnostics for sexually transmitted diseases market are concentrating on developing groundbreaking solutions, particularly rapid point-of-care polymerase chain reaction (PCR) devices, to boost diagnostic speed, accuracy, and accessibility. These rapid point-of-care PCR devices are portable molecular diagnostic instruments that integrate sample preparation, amplification, and detection into one compact unit, allowing for timely and highly sensitive pathogen identification outside traditional laboratory environments. For instance, in March 2025, Visby Medical, a US-based diagnostic technology firm, launched the Visby Medical Women’s Sexual Health Test. This product is a single-use, handheld PCR device crafted to identify chlamydia, gonorrhea, and trichomoniasis from vaginal samples in 30 minutes. It functions independently, requiring no external instrumentation or cold-chain logistics, features an embedded amplification system, and delivers lab-quality outcomes directly at the point of care to support swift clinical decisions. Authorized for prescription home use, it marks the first U.S. Food and Drug Administration (FDA)-cleared molecular diagnostic test for multiple sexually transmitted infections (STIs) applicable outside clinical settings. This launch underscores a move toward decentralized diagnostic options that enhance accessibility, especially for underserved or remote populations.

Which Companies Are Engaged In The Molecular Diagnostics For Sexually Transmitted Diseases Market Environment?

Major companies operating in the molecular diagnostics for sexually transmitted diseases market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Hologic Inc., bioMérieux S.A., QuidelOrtho Corporation, QIAGEN N.V., Cepheid, Sansure Biotech Inc., OraSure Technologies Inc., Meridian Bioscience, Seegene Inc., Visby Medical Inc., Zeesan Biotech, Binx Health Inc., GCC Biotech, GeneProof, Solone Life Sciences India (P) Ltd.

Access The Complete Molecular Diagnostics For Sexually Transmitted Diseases Market Report:

https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-for-sexually-transmitted-diseases-global-market-report

Which Region Stands As The Largest Contributor To The Molecular Diagnostics For Sexually Transmitted Diseases Market?

North America was the largest region in the molecular diagnostics for sexually transmitted diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molecular diagnostics for sexually transmitted diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Molecular Diagnostics For Sexually Transmitted Diseases Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-for-sexually-transmitted-diseases-global-market-report

Browse Through More Reports Similar to the Global Molecular Diagnostics For Sexually Transmitted Diseases Market 2026, By The Business Research Company

Trade Credit Insurance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-credit-insurance-global-market-report

Household Insecticides Market Report 2026

https://www.thebusinessresearchcompany.com/report/household-insecticides-global-market-report

Household Lending Market Report 2026

https://www.thebusinessresearchcompany.com/report/household-lending-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Molecular Diagnostics For Sexually Transmitted Diseases Market Between 2026 And 2030? _x000D_

The market size for molecular diagnostics used in sexually transmitted diseases has experienced significant growth recently. It is anticipated to increase from $3.67 billion in 2025 to $4.07 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.7%. The expansion observed in past periods can be linked to factors like the reliance on traditional serological tests, the limited availability of automated PCR systems, a lack of awareness regarding molecular diagnostics in emerging markets, the rising prevalence of sexually transmitted infections, and the labor-intensive nature of manual workflows and testing._x000D_

_x000D_

The molecular diagnostics for sexually transmitted diseases market size is anticipated to undergo significant expansion in the upcoming years, with projections indicating it will reach **$6.05 billion in 2030**, exhibiting a compound annual growth rate (**CAGR**) of **10.4%**. This expected growth during the forecast period is driven by factors such as technological advancements in automated PCR and nucleic acid extraction, the widening availability of point-of-care molecular diagnostics, improvements in healthcare infrastructure within developing regions, the increasing implementation of laboratory information management systems (LIMS), and rising investment in research and development for rapid and multiplexed diagnostic assays. Key developments characterizing this period include the growing adoption of nucleic acid-based testing methods, the expansion of point-of-care molecular diagnostic solutions, a heightened demand for rapid and accurate STD detection, the integration of molecular diagnostics with laboratory information systems, and progress in automated PCR and high-throughput diagnostic platforms._x000D_

_x000D_

#Access Your Free Sample Report For In-Depth Market Analysis:#_x000D_

https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-for-sexually-transmitted-diseases-global-market-report_x000D_

_x000D_

What Leading Drivers Are Supporting The Molecular Diagnostics For Sexually Transmitted Diseases Market Expansion?_x000D_

The increasing occurrence of sexually transmitted infections (STIs) is anticipated to drive the expansion of the molecular diagnostics for sexually transmitted diseases market in the future. STIs are defined as infections stemming from bacteria, viruses, or parasites, spread via sexual contact, impacting both the reproductive and urinary systems. The rise in STIs is predominantly attributed to irregular application of protective measures, which contributes to simpler transmission of infections among those who are sexually active. Molecular diagnostics for STIs are crucial in controlling these infections, as they allow for prompt and precise identification of pathogens, even when individuals show no symptoms, thereby aiding immediate treatment, decreasing disease spread, and enhancing overall patient health. For example, data released in June 2024 by the UK Health Security Agency (UKHSA), a UK government body, indicated 401,800 new STI diagnoses in England during 2023. This represented a 4.7% rise from the 383,789 cases documented in 2022. Consequently, the growing prevalence of sexually transmitted infections acts as a significant catalyst for the molecular diagnostics for sexually transmitted diseases market’s growth._x000D_

_x000D_

How Is The Molecular Diagnostics For Sexually Transmitted Diseases Market Categorized Across Its Segment Groups?_x000D_

The molecular diagnostics for sexually transmitted diseases market covered in this report is segmented – _x000D_

_x000D_

1) By Product: Instruments And Services, Consumables, Software_x000D_

2) By Technology: Laboratory Testing, Point-Of-Care Testing_x000D_

3) By Application: Chlamydia Trachomatis (CT) Or Neisseria Gonorrhoeae (NG) Testing, Syphilis Testing, Gonorrhea Testing, Herpes Simplex Virus (HSV) Testing, Human Papillomavirus (HPV) Testing, Human Immunodeficiency Virus (HIV) Testing, Trichomonas, Ureaplasma And Mycoplasma, Other Applications_x000D_

_x000D_

Subsegments:_x000D_

1) By Instruments And Services: Molecular Diagnostic Analyzers, Automated Polymerase Chain Reaction Systems, Nucleic Acid Extraction Instruments, Diagnostic Service Providers, Maintenance And Calibration Services, Installation And Training Services_x000D_

2) By Consumables: Deoxyribonucleic Acid Extraction Kits, Ribonucleic Acid Extraction Kits, Polymerase Chain Reaction Reagents, Nucleic Acid Probes, Control And Reference Standards, Detection Enzymes And Buffers_x000D_

3) By Software: Data Interpretation And Reporting Software, Polymerase Chain Reaction Workflow Management Software, Laboratory Information Management Systems, Diagnostic Decision Support Software, Quality Control Monitoring Software_x000D_

_x000D_

What Emerging Trends Are Seen In The Molecular Diagnostics For Sexually Transmitted Diseases Market?_x000D_

Companies operating within the molecular diagnostics for sexually transmitted diseases market are concentrating on developing advanced solutions, such as rapid point-of-care polymerase chain reaction (PCR) devices, to enhance diagnostic speed, accuracy, and accessibility. These rapid point-of-care PCR devices are portable molecular diagnostic tools that integrate sample preparation, amplification, and detection into a single, compact unit, facilitating timely and highly sensitive pathogen detection outside traditional laboratory settings. For instance, in March 2025, Visby Medical, a US-based diagnostic technology company, launched the Visby Medical Women’s Sexual Health Test. This product is a single-use, handheld PCR device engineered to identify chlamydia, gonorrhea, and trichomoniasis from vaginal samples within 30 minutes. It operates without requiring external instrumentation or cold-chain logistics, includes an integrated amplification system, and provides lab-quality results directly at the point of care to support immediate clinical decisions. The test is authorized for prescription home use, making it the first U.S. Food and Drug Administration (FDA)-cleared molecular diagnostic test for multiple sexually transmitted infections (STIs) that can be utilized outside clinical environments. This launch indicates a progression toward decentralized diagnostic solutions that increase availability, particularly for underserved or remote populations._x000D_

_x000D_

Which Firms Are Influencing Competition In The Molecular Diagnostics For Sexually Transmitted Diseases Market?_x000D_

Major companies operating in the molecular diagnostics for sexually transmitted diseases market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Hologic Inc., bioMérieux S.A., QuidelOrtho Corporation, QIAGEN N.V., Cepheid, Sansure Biotech Inc., OraSure Technologies Inc., Meridian Bioscience, Seegene Inc., Visby Medical Inc., Zeesan Biotech, Binx Health Inc., GCC Biotech, GeneProof, Solone Life Sciences India (P) Ltd. _x000D_

_x000D_

#Get The Full Molecular Diagnostics For Sexually Transmitted Diseases Market Report:#_x000D_

https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-for-sexually-transmitted-diseases-global-market-report_x000D_

_x000D_

Where Is The Molecular Diagnostics For Sexually Transmitted Diseases Market Primarily Concentrated By Region?_x000D_

North America was the largest region in the molecular diagnostics for sexually transmitted diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molecular diagnostics for sexually transmitted diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request A Customized Molecular Diagnostics For Sexually Transmitted Diseases Market Report For Competitive Insights:#_x000D_

https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-for-sexually-transmitted-diseases-global-market-report_x000D_

_x000D_

#Browse Through More Reports Similar to the Global Molecular Diagnostics For Sexually Transmitted Diseases Market 2026, By The Business Research Company#_x000D_

_x000D_

Trade Credit Insurance Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/trade-credit-insurance-global-market-report_x000D_

_x000D_

Household Insecticides Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/household-insecticides-global-market-report_x000D_

_x000D_

Household Lending Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/household-lending-global-market-report_x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Molecular Diagnostics For Sexually Transmitted Diseases Market Between 2026 And 2030?

The market size for molecular diagnostics used in sexually transmitted diseases has experienced significant growth recently. It is anticipated to increase from $3.67 billion in 2025 to $4.07 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.7%. The expansion observed in past periods can be linked to factors like the reliance on traditional serological tests, the limited availability of automated PCR systems, a lack of awareness regarding molecular diagnostics in emerging markets, the rising prevalence of sexually transmitted infections, and the labor-intensive nature of manual workflows and testing.

The molecular diagnostics for sexually transmitted diseases market size is anticipated to undergo significant expansion in the upcoming years, with projections indicating it will reach **$6.05 billion in 2030**, exhibiting a compound annual growth rate (**CAGR**) of **10.4%**. This expected growth during the forecast period is driven by factors such as technological advancements in automated PCR and nucleic acid extraction, the widening availability of point-of-care molecular diagnostics, improvements in healthcare infrastructure within developing regions, the increasing implementation of laboratory information management systems (LIMS), and rising investment in research and development for rapid and multiplexed diagnostic assays. Key developments characterizing this period include the growing adoption of nucleic acid-based testing methods, the expansion of point-of-care molecular diagnostic solutions, a heightened demand for rapid and accurate STD detection, the integration of molecular diagnostics with laboratory information systems, and progress in automated PCR and high-throughput diagnostic platforms.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-for-sexually-transmitted-diseases-global-market-report

What Leading Drivers Are Supporting The Molecular Diagnostics For Sexually Transmitted Diseases Market Expansion?

The increasing occurrence of sexually transmitted infections (STIs) is anticipated to drive the expansion of the molecular diagnostics for sexually transmitted diseases market in the future. STIs are defined as infections stemming from bacteria, viruses, or parasites, spread via sexual contact, impacting both the reproductive and urinary systems. The rise in STIs is predominantly attributed to irregular application of protective measures, which contributes to simpler transmission of infections among those who are sexually active. Molecular diagnostics for STIs are crucial in controlling these infections, as they allow for prompt and precise identification of pathogens, even when individuals show no symptoms, thereby aiding immediate treatment, decreasing disease spread, and enhancing overall patient health. For example, data released in June 2024 by the UK Health Security Agency (UKHSA), a UK government body, indicated 401,800 new STI diagnoses in England during 2023. This represented a 4.7% rise from the 383,789 cases documented in 2022. Consequently, the growing prevalence of sexually transmitted infections acts as a significant catalyst for the molecular diagnostics for sexually transmitted diseases market’s growth.

How Is The Molecular Diagnostics For Sexually Transmitted Diseases Market Categorized Across Its Segment Groups?

The molecular diagnostics for sexually transmitted diseases market covered in this report is segmented –

1) By Product: Instruments And Services, Consumables, Software

2) By Technology: Laboratory Testing, Point-Of-Care Testing

3) By Application: Chlamydia Trachomatis (CT) Or Neisseria Gonorrhoeae (NG) Testing, Syphilis Testing, Gonorrhea Testing, Herpes Simplex Virus (HSV) Testing, Human Papillomavirus (HPV) Testing, Human Immunodeficiency Virus (HIV) Testing, Trichomonas, Ureaplasma And Mycoplasma, Other Applications

Subsegments:

1) By Instruments And Services: Molecular Diagnostic Analyzers, Automated Polymerase Chain Reaction Systems, Nucleic Acid Extraction Instruments, Diagnostic Service Providers, Maintenance And Calibration Services, Installation And Training Services

2) By Consumables: Deoxyribonucleic Acid Extraction Kits, Ribonucleic Acid Extraction Kits, Polymerase Chain Reaction Reagents, Nucleic Acid Probes, Control And Reference Standards, Detection Enzymes And Buffers

3) By Software: Data Interpretation And Reporting Software, Polymerase Chain Reaction Workflow Management Software, Laboratory Information Management Systems, Diagnostic Decision Support Software, Quality Control Monitoring Software

What Emerging Trends Are Seen In The Molecular Diagnostics For Sexually Transmitted Diseases Market?

Companies operating within the molecular diagnostics for sexually transmitted diseases market are concentrating on developing advanced solutions, such as rapid point-of-care polymerase chain reaction (PCR) devices, to enhance diagnostic speed, accuracy, and accessibility. These rapid point-of-care PCR devices are portable molecular diagnostic tools that integrate sample preparation, amplification, and detection into a single, compact unit, facilitating timely and highly sensitive pathogen detection outside traditional laboratory settings. For instance, in March 2025, Visby Medical, a US-based diagnostic technology company, launched the Visby Medical Women’s Sexual Health Test. This product is a single-use, handheld PCR device engineered to identify chlamydia, gonorrhea, and trichomoniasis from vaginal samples within 30 minutes. It operates without requiring external instrumentation or cold-chain logistics, includes an integrated amplification system, and provides lab-quality results directly at the point of care to support immediate clinical decisions. The test is authorized for prescription home use, making it the first U.S. Food and Drug Administration (FDA)-cleared molecular diagnostic test for multiple sexually transmitted infections (STIs) that can be utilized outside clinical environments. This launch indicates a progression toward decentralized diagnostic solutions that increase availability, particularly for underserved or remote populations.

Which Firms Are Influencing Competition In The Molecular Diagnostics For Sexually Transmitted Diseases Market?

Major companies operating in the molecular diagnostics for sexually transmitted diseases market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Hologic Inc., bioMérieux S.A., QuidelOrtho Corporation, QIAGEN N.V., Cepheid, Sansure Biotech Inc., OraSure Technologies Inc., Meridian Bioscience, Seegene Inc., Visby Medical Inc., Zeesan Biotech, Binx Health Inc., GCC Biotech, GeneProof, Solone Life Sciences India (P) Ltd.

Get The Full Molecular Diagnostics For Sexually Transmitted Diseases Market Report:

https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-for-sexually-transmitted-diseases-global-market-report

Where Is The Molecular Diagnostics For Sexually Transmitted Diseases Market Primarily Concentrated By Region?

North America was the largest region in the molecular diagnostics for sexually transmitted diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molecular diagnostics for sexually transmitted diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Molecular Diagnostics For Sexually Transmitted Diseases Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-for-sexually-transmitted-diseases-global-market-report

Browse Through More Reports Similar to the Global Molecular Diagnostics For Sexually Transmitted Diseases Market 2026, By The Business Research Company

Trade Credit Insurance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-credit-insurance-global-market-report

Household Insecticides Market Report 2026

https://www.thebusinessresearchcompany.com/report/household-insecticides-global-market-report

Household Lending Market Report 2026

https://www.thebusinessresearchcompany.com/report/household-lending-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Molecular Diagnostics For Sexually Transmitted Diseases Market Over The 2026–2030 Period?

The market size for molecular diagnostics focused on sexually transmitted diseases has witnessed rapid expansion in recent years. This sector is anticipated to increase from $3.67 billion in 2025 to $4.07 billion in 2026, at a compound annual growth rate (CAGR) of 10.7%. In the past, this growth was influenced by factors including a reliance on conventional serological tests, the constrained availability of automated PCR systems, inadequate awareness of molecular diagnostics in nascent markets, a rising incidence of sexually transmitted infections, and testing processes characterized by manual workflows and intensive labor.

The molecular diagnostics for sexually transmitted diseases market size is projected to experience rapid growth in the coming years, with forecasts indicating it will reach $6.05 billion in 2030, driven by a compound annual growth rate (CAGR) of 10.4%. This expansion during the forecast period can be attributed to advancements in automated PCR and nucleic acid extraction technologies, the broadening availability of point-of-care molecular diagnostics, improvements in healthcare infrastructure across developing regions, the increasing adoption of laboratory information management systems (LIMS), and growing investment in research and development for rapid and multiplexed diagnostic assays. Key trends anticipated in the forecast period include the escalating use of nucleic acid-based testing methods, the proliferation of point-of-care molecular diagnostic solutions, an increasing demand for quick and accurate STD detection, the integration of molecular diagnostics with laboratory information systems, and the advancement of automated PCR and high-throughput diagnostic platforms.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27351&type=smp

What Underlying Factors Are Accelerating The Growth Of The Molecular Diagnostics For Sexually Transmitted Diseases Market?

The escalating incidence of sexually transmitted infections is projected to advance the molecular diagnostics for sexually transmitted diseases market in the coming years. Sexually transmitted infections (STIs) refer to health conditions caused by bacteria, viruses, or parasites that are transmitted through sexual contact, affecting the reproductive and urinary systems. The increasing prevalence of STIs largely stems from the inconsistent application of protection methods, which in turn facilitates the easier spread of infections among sexually active individuals. Molecular diagnostics for sexually transmitted infections (STIs) play a vital role in managing these conditions by enabling the early and precise identification of pathogens, even in asymptomatic cases, thereby allowing for timely treatment, reducing disease transmission, and enhancing overall patient recovery. For instance, in June 2024, according to the UK Health Security Agency (UKHSA), England recorded 401,800 new STI diagnoses in 2023, an increase of 4.7% compared to the 383,789 cases reported in 2022. Therefore, the rising prevalence of sexually transmitted infections is a key driver for the growth of the molecular diagnostics for sexually transmitted diseases market.

How Is The Molecular Diagnostics For Sexually Transmitted Diseases Market Segmented Across Key Categories?

The molecular diagnostics for sexually transmitted diseases market covered in this report is segmented –

1) By Product: Instruments And Services, Consumables, Software

2) By Technology: Laboratory Testing, Point-Of-Care Testing

3) By Application: Chlamydia Trachomatis (CT) Or Neisseria Gonorrhoeae (NG) Testing, Syphilis Testing, Gonorrhea Testing, Herpes Simplex Virus (HSV) Testing, Human Papillomavirus (HPV) Testing, Human Immunodeficiency Virus (HIV) Testing, Trichomonas, Ureaplasma And Mycoplasma, Other Applications

Subsegments:

1) By Instruments And Services: Molecular Diagnostic Analyzers, Automated Polymerase Chain Reaction Systems, Nucleic Acid Extraction Instruments, Diagnostic Service Providers, Maintenance And Calibration Services, Installation And Training Services

2) By Consumables: Deoxyribonucleic Acid Extraction Kits, Ribonucleic Acid Extraction Kits, Polymerase Chain Reaction Reagents, Nucleic Acid Probes, Control And Reference Standards, Detection Enzymes And Buffers

3) By Software: Data Interpretation And Reporting Software, Polymerase Chain Reaction Workflow Management Software, Laboratory Information Management Systems, Diagnostic Decision Support Software, Quality Control Monitoring Software

Which Upcoming Trends Are Expected To Influence The Molecular Diagnostics For Sexually Transmitted Diseases Market?

Major corporations within the molecular diagnostics for sexually transmitted diseases market are prioritizing the development of innovative solutions, such as rapid point-of-care polymerase chain reaction (PCR) devices, to enhance diagnostic speed, accuracy, and accessibility. These rapid point-of-care PCR devices are portable molecular diagnostic tools that integrate sample preparation, amplification, and detection into a single, compact unit, allowing for timely and highly sensitive pathogen detection outside traditional laboratory settings. For instance, in March 2025, Visby Medical, a US-based diagnostic technology company, introduced the Visby Medical Women’s Sexual Health Test. This product is a single-use, handheld PCR device engineered to identify chlamydia, gonorrhea, and trichomoniasis from vaginal samples within 30 minutes. It operates without the need for external instrumentation or cold-chain logistics, incorporates an integrated amplification system, and provides lab-quality results directly at the point of care to support immediate clinical decisions. The test is authorized for prescription home use, making it the first U.S. Food and Drug Administration (FDA)-cleared molecular diagnostic test for multiple sexually transmitted infections (STIs) that can be utilized outside clinical settings. This launch signifies a transition towards decentralized diagnostic solutions that broaden accessibility, especially for underserved or remote populations.

Who Are The Dominant Players Shaping The Molecular Diagnostics For Sexually Transmitted Diseases Market Landscape?

Major companies operating in the molecular diagnostics for sexually transmitted diseases market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Hologic Inc., bioMérieux S.A., QuidelOrtho Corporation, QIAGEN N.V., Cepheid, Sansure Biotech Inc., OraSure Technologies Inc., Meridian Bioscience, Seegene Inc., Visby Medical Inc., Zeesan Biotech, Binx Health Inc., GCC Biotech, GeneProof, Solone Life Sciences India (P) Ltd.

Read the full molecular diagnostics for sexually transmitted diseases market report here:

https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-for-sexually-transmitted-diseases-global-market-report

Which Region Is Projected To Dominate The Molecular Diagnostics For Sexually Transmitted Diseases Market During The Forecast Period?

North America was the largest region in the molecular diagnostics for sexually transmitted diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molecular diagnostics for sexually transmitted diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Molecular Diagnostics For Sexually Transmitted Diseases Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27351&type=smp

Browse Through More Reports Similar to the Global Molecular Diagnostics For Sexually Transmitted Diseases Market 2026, By The Business Research Company

Trade Credit Insurance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-credit-insurance-global-market-report

Household Insecticides Market Report 2026

https://www.thebusinessresearchcompany.com/report/household-insecticides-global-market-report

Household Lending Market Report 2026

https://www.thebusinessresearchcompany.com/report/household-lending-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the worker heat stress monitoring wearable market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Molecular Diagnostics For Sexually Transmitted Diseases Market show for the 2026–2030 period?

The market size for molecular diagnostics for sexually transmitted diseases has shown rapid expansion in recent years. It is projected to increase from $3.67 billion in 2025 to $4.07 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.7%. The historical growth can be attributed to factors like reliance on conventional serological tests, limited availability of automated pcr systems, low awareness of molecular diagnostics in emerging markets, the growing prevalence of sexually transmitted infections, and manual workflow alongside labor-intensive testing.

The market for molecular diagnostics focused on sexually transmitted diseases is expected to demonstrate significant expansion in the coming years. It is projected to achieve a size of $6.05 billion by 2030, with a compound annual growth rate (CAGR) of 10.4%. This anticipated growth can be attributed to various factors, including technological progress in automated PCR and nucleic acid extraction, the wider implementation of point-of-care molecular diagnostics, improved healthcare infrastructure in developing regions, the increasing embrace of laboratory information management systems (LIMS), and intensified investment in research and development for rapid and multiplexed diagnostic assays. Prominent trends throughout the forecast period involve a growing preference for nucleic acid-based testing methods, the proliferation of point-of-care molecular diagnostic solutions, an escalating requirement for swift and accurate STD detection, the integration of molecular diagnostics with existing laboratory information systems, and the advancement of automated PCR and high-throughput diagnostic platforms.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27351&type=smp

What Drivers Are Shaping The Development Of The Molecular Diagnostics For Sexually Transmitted Diseases Market?

The increasing occurrence of sexually transmitted infections (STIs) is projected to propel the growth of the molecular diagnostics for sexually transmitted diseases market. These infections, caused by bacteria, viruses, or parasites, are transmitted through sexual contact and primarily impact the reproductive and urinary systems. The prevalence of STIs is escalating mainly due to inconsistent use of protection methods, which allows for easier transmission among sexually active individuals. Molecular diagnostics for STIs are crucial in managing these infections by enabling early and accurate detection of pathogens, even in asymptomatic cases, facilitating timely treatment, reducing disease spread, and enhancing overall patient outcomes. For instance, in June 2024, the UK Health Security Agency (UKHSA) stated that England recorded 401,800 new STI diagnoses in 2023, a 4.7% increase from the 383,789 cases reported in 2022. Consequently, the rising prevalence of sexually transmitted infections is fueling the expansion of the molecular diagnostics for sexually transmitted diseases market.

Which Segments Are Contributing To The Growth Of The Molecular Diagnostics For Sexually Transmitted Diseases Market?

The molecular diagnostics for sexually transmitted diseases market covered in this report is segmented –

1) By Product: Instruments And Services, Consumables, Software

2) By Technology: Laboratory Testing, Point-Of-Care Testing

3) By Application: Chlamydia Trachomatis (CT) Or Neisseria Gonorrhoeae (NG) Testing, Syphilis Testing, Gonorrhea Testing, Herpes Simplex Virus (HSV) Testing, Human Papillomavirus (HPV) Testing, Human Immunodeficiency Virus (HIV) Testing, Trichomonas, Ureaplasma And Mycoplasma, Other Applications

Subsegments:

1) By Instruments And Services: Molecular Diagnostic Analyzers, Automated Polymerase Chain Reaction Systems, Nucleic Acid Extraction Instruments, Diagnostic Service Providers, Maintenance And Calibration Services, Installation And Training Services

2) By Consumables: Deoxyribonucleic Acid Extraction Kits, Ribonucleic Acid Extraction Kits, Polymerase Chain Reaction Reagents, Nucleic Acid Probes, Control And Reference Standards, Detection Enzymes And Buffers

3) By Software: Data Interpretation And Reporting Software, Polymerase Chain Reaction Workflow Management Software, Laboratory Information Management Systems, Diagnostic Decision Support Software, Quality Control Monitoring Software

What Trends Are Reshaping The Dynamics Of The Molecular Diagnostics For Sexually Transmitted Diseases Market?

Leading companies in the molecular diagnostics sector for sexually transmitted diseases are prioritizing the creation of advanced tools, including rapid point-of-care polymerase chain reaction (PCR) devices, to enhance diagnostic speed, precision, and reach. These portable molecular diagnostic instruments integrate sample handling, amplification, and detection within one compact unit, facilitating quick and highly sensitive identification of pathogens beyond conventional lab environments. An illustrative instance is Visby Medical, a US diagnostic technology firm, which introduced the Visby Medical Women’s Sexual Health Test in March 2025. This single-use, handheld PCR device is engineered to detect chlamydia, gonorrhea, and trichomoniasis from vaginal samples in just 30 minutes. It functions independently, requiring no external equipment or cold-chain storage, includes an embedded amplification system, and delivers laboratory-grade results at the point of care, aiding swift clinical choices. Authorized for prescription home use, it marks the first U.S. Food and Drug Administration (FDA)-approved molecular diagnostic test for multiple sexually transmitted infections (STIs) deployable outside clinical environments. Such an introduction signifies a movement towards decentralized diagnostic approaches, thereby boosting accessibility, particularly for populations in remote or underserved areas.

Who Are The Top-Performing Companies In The Molecular Diagnostics For Sexually Transmitted Diseases Market In Recent Years?

Major companies operating in the molecular diagnostics for sexually transmitted diseases market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Hologic Inc., bioMérieux S.A., QuidelOrtho Corporation, QIAGEN N.V., Cepheid, Sansure Biotech Inc., OraSure Technologies Inc., Meridian Bioscience, Seegene Inc., Visby Medical Inc., Zeesan Biotech, Binx Health Inc., GCC Biotech, GeneProof, Solone Life Sciences India (P) Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-for-sexually-transmitted-diseases-global-market-report

How Does The Molecular Diagnostics For Sexually Transmitted Diseases Market Perform Across Major Global Regions?

North America was the largest region in the molecular diagnostics for sexually transmitted diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molecular diagnostics for sexually transmitted diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Molecular Diagnostics For Sexually Transmitted Diseases Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27351&type=smp

Browse Through More Reports Similar to the Global Molecular Diagnostics For Sexually Transmitted Diseases Market 2026, By The Business Research Company

Trade Credit Insurance Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-credit-insurance-global-market-report

Household Insecticides Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/household-insecticides-global-market-report

Household Lending Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/household-lending-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Uncover key drivers, emerging technologies, and competitive movements shaping the molecular diagnostics for sexually transmitted diseases market from 2025–2034 with trusted insights from The Business Research Company

What Are The Market Size Estimates For The Molecular Diagnostics For Sexually Transmitted Diseases Market?

The market size for molecular diagnostics addressing sexually transmitted diseases has experienced substantial growth in recent years. This market is forecasted to expand from $3.31 billion in 2024 to $3.67 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 10.9%. Historically, this growth can be credited to the escalating prevalence of sexually transmitted infections, the increasing utilization of nucleic acid amplification tests, enhanced awareness fostered by government screening programs, backing from global health organizations, and swift adoption in diagnostic laboratories.

The molecular diagnostics for sexually transmitted diseases market size is poised for substantial growth over the next few years, with projections indicating it will reach $5.48 billion by 2029, growing at a compound annual growth rate (CAGR) of 10.5%. This anticipated expansion during the forecast period can be attributed to an increased focus on early disease detection, a rising need for personalized diagnostics, the extension of sexually transmitted infection surveillance initiatives, the proliferation of public-private partnerships, and an escalating preference for non-invasive testing methodologies. Key developments expected in this period include technological advancements in molecular assay platforms, innovations in point-of-care diagnostic devices, the development of multiplex polymerase chain reaction (PCR)-based testing panels, dedicated research and development for portable and automated systems, and the incorporation of artificial intelligence in interpreting diagnostic results.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27351&type=smp

Which Industry Forces Are Driving The Molecular Diagnostics For Sexually Transmitted Diseases Market Forward?

The increasing incidence of sexually transmitted infections is anticipated to boost the expansion of the molecular diagnostics for sexually transmitted diseases market in the future. Sexually transmitted infections, or STIs, are infections resulting from bacteria, viruses, or parasites passed during sexual contact, impacting the reproductive and urinary systems. The rising occurrence of STIs largely stems from irregular use of protective measures. This insufficient protection contributes to the simpler spread of these infections among sexually active people. Molecular diagnostic tools for sexually transmitted infections (STIs) are vital in managing these conditions, as they allow for the prompt and precise identification of pathogens, even in individuals without symptoms, thereby supporting swift treatment, lowering disease transmission, and enhancing patient well-being. As an illustration, in January 2024, the National Association of County and City Health Officials (NACCHO), a US-based nonprofit organization, reported 3,755 cases of congenital syphilis, indicating a 31% increase between 2021 and 2022. Consequently, the escalating prevalence of sexually transmitted infections is fueling the expansion of the molecular diagnostics for sexually transmitted diseases market.

How Is The Molecular Diagnostics For Sexually Transmitted Diseases Market Organized By Different Segments?

The molecular diagnostics for sexually transmitted diseases market covered in this report is segmented

1) By Product: Instruments And Services, Consumables, Software

2) By Technology: Laboratory Testing, Point-Of-Care Testing

3) By Application: Chlamydia Trachomatis (CT) Or Neisseria Gonorrhoeae (NG) Testing, Syphilis Testing, Gonorrhea Testing, Herpes Simplex Virus (HSV) Testing, Human Papillomavirus (HPV) Testing, Human Immunodeficiency Virus (HIV) Testing, Trichomonas, Ureaplasma And Mycoplasma, Other Applications

Subsegment:

1) By Instruments And Services: Molecular Diagnostic Analyzers, Automated Polymerase Chain Reaction Systems, Nucleic Acid Extraction Instruments, Diagnostic Service Providers, Maintenance And Calibration Services, Installation And Training Services

2) By Consumables: Deoxyribonucleic Acid Extraction Kits, Ribonucleic Acid Extraction Kits, Polymerase Chain Reaction Reagents, Nucleic Acid Probes, Control And Reference Standards, Detection Enzymes And Buffers

3) By Software: Data Interpretation And Reporting Software, Polymerase Chain Reaction Workflow Management Software, Laboratory Information Management Systems, Diagnostic Decision Support Software, Quality Control Monitoring Software

What Current And Upcoming Trends Are Shaping The Molecular Diagnostics For Sexually Transmitted Diseases Market?

Leading companies in the molecular diagnostics for sexually transmitted diseases market are dedicated to developing innovative solutions, such as swift point-of-care polymerase chain reaction (PCR) devices, to enhance diagnostic speed, accuracy, and accessibility. These rapid point-of-care polymerase chain reaction (PCR) devices are portable molecular diagnostic tools that integrate sample preparation, amplification, and detection into a singular, compact unit, facilitating timely and highly sensitive pathogen detection outside conventional laboratory environments. As an illustration, in March 2025, Visby Medical, a US-based diagnostic technology company, introduced the Visby Medical Women’s Sexual Health Test. This product is a single-use, handheld PCR device crafted to identify chlamydia, gonorrhea, and trichomoniasis from vaginal samples within 30 minutes. It operates without requiring external instrumentation or cold-chain logistics, includes an integrated amplification system, and delivers lab-quality results directly at the point of care to enable prompt clinical decisions. The test is approved for prescription home use, establishing it as the first U.S. Food and Drug Administration (FDA)-cleared molecular diagnostic test for multiple sexually transmitted infections (STIs) that can be utilized beyond clinical settings. This launch underscores a shift towards decentralized diagnostic solutions that improve accessibility, particularly for underserved or remote populations.

Who Are The Primary Market Leaders In The Molecular Diagnostics For Sexually Transmitted Diseases Market?

Major companies operating in the molecular diagnostics for sexually transmitted diseases market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Hologic Inc., bioMérieux S.A., QuidelOrtho Corporation, QIAGEN N.V., Cepheid, Sansure Biotech Inc., OraSure Technologies Inc., Meridian Bioscience, Seegene Inc., Visby Medical Inc., Zeesan Biotech, Binx Health Inc., GCC Biotech, GeneProof, and Solone Life Sciences India (P) Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-for-sexually-transmitted-diseases-global-market-report

How Do Regional Dynamics Influence The Molecular Diagnostics For Sexually Transmitted Diseases Market Performance?

North America was the largest region in the molecular diagnostics for sexually transmitted diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molecular diagnostics for sexually transmitted diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=27351&type=smp

Browse Through More Reports Similar to the Global Molecular Diagnostics For Sexually Transmitted Diseases Market 2025, By The Business Research Company

Personal Loans Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/personal-loans-global-market-report

Household Insecticides Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/household-insecticides-global-market-report

Household Lending Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/household-lending-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Molecular Diagnostics For Sexually Transmitted Diseases Industry In 2025?

The market size for molecular diagnostics of sexually transmitted diseases has experienced swift expansion recently. This market is projected to expand from $3.31 billion in 2024 to $3.67 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 10.9%. Historically, this growth stemmed from factors such as the increasing prevalence of sexually transmitted infections, the expanded application of nucleic acid amplification tests, enhanced awareness driven by government screening initiatives, backing from international health organizations, and prompt integration within diagnostic laboratories.

The molecular diagnostics for sexually transmitted diseases market size is projected to experience substantial expansion over the next few years, with an anticipated growth to $5.48 billion by 2029, at a compound annual growth rate (CAGR) of 10.5%. This growth in the forecast period is primarily driven by an increased focus on early disease detection, a rising demand for personalized diagnostics, the expansion of sexually transmitted infection surveillance programs, a proliferation of public-private partnerships, and a growing preference for non-invasive testing methods. Prominent trends throughout this period are expected to encompass technological advancements in molecular assay platforms, innovations in point-of-care diagnostic devices, the development of multiplex polymerase chain reaction (PCR)-based testing panels, continuous research and development in portable and automated systems, and the integration of artificial intelligence in result interpretation.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27351&type=smp

What Are The Drivers Pushing New Developments In The Molecular Diagnostics For Sexually Transmitted Diseases Market?

The market for molecular diagnostics for sexually transmitted diseases is anticipated to expand due to the increasing incidence of sexually transmitted infections. Sexually transmitted infections (STIs) are defined as ailments resulting from bacteria, viruses, or parasites passed during sexual activity, impacting the reproductive and urinary systems. The growing occurrence of sexually transmitted infections is predominantly linked to inconsistent adoption of protective measures. This inadequate use of protection leads to simpler transmission of these infections among sexually active people. Molecular diagnostics for sexually transmitted infections (STIs) are crucial for managing these conditions, as they allow for prompt and precise identification of pathogens, even in those without symptoms, thereby enabling early treatment, curbing disease spread, and enhancing patient well-being. An illustrative example from January 2024, provided by the National Association of County and City Health Officials (NACCHO), a US-based nonprofit organization, indicated that 3,755 congenital syphilis cases were reported, showing a 31% rise between 2021 and 2022. Consequently, the increasing prevalence of sexually transmitted infections is fueling the expansion of the molecular diagnostics for sexually transmitted diseases market.

What Are The Major Segment Types Covered In The Molecular Diagnostics For Sexually Transmitted Diseases Market?

The molecular diagnostics for sexually transmitted diseases market covered in this report is segmented

1) By Product: Instruments And Services, Consumables, Software

2) By Technology: Laboratory Testing, Point-Of-Care Testing

3) By Application: Chlamydia Trachomatis (CT) Or Neisseria Gonorrhoeae (NG) Testing, Syphilis Testing, Gonorrhea Testing, Herpes Simplex Virus (HSV) Testing, Human Papillomavirus (HPV) Testing, Human Immunodeficiency Virus (HIV) Testing, Trichomonas, Ureaplasma And Mycoplasma, Other Applications

Subsegment:

1) By Instruments And Services: Molecular Diagnostic Analyzers, Automated Polymerase Chain Reaction Systems, Nucleic Acid Extraction Instruments, Diagnostic Service Providers, Maintenance And Calibration Services, Installation And Training Services

2) By Consumables: Deoxyribonucleic Acid Extraction Kits, Ribonucleic Acid Extraction Kits, Polymerase Chain Reaction Reagents, Nucleic Acid Probes, Control And Reference Standards, Detection Enzymes And Buffers

3) By Software: Data Interpretation And Reporting Software, Polymerase Chain Reaction Workflow Management Software, Laboratory Information Management Systems, Diagnostic Decision Support Software, Quality Control Monitoring Software

Which Key Trends Are Expected To Influence The Molecular Diagnostics For Sexually Transmitted Diseases Market In The Coming Years?

Companies operating in the molecular diagnostics for sexually transmitted diseases market are increasingly focusing on creating advanced solutions, specifically rapid point-of-care polymerase chain reaction (PCR) devices, to boost diagnostic speed, accuracy, and accessibility. These swift point-of-care PCR devices are mobile molecular diagnostic tools that merge sample preparation, amplification, and detection into one compact unit, enabling quick and highly sensitive pathogen detection away from traditional laboratory settings. For example, in March 2025, Visby Medical, a US-based diagnostic technology company, launched the Visby Medical Women’s Sexual Health Test. This product is a single-use, handheld PCR device engineered to identify chlamydia, gonorrhea, and trichomoniasis from vaginal samples within 30 minutes. It operates without requiring external instrumentation or cold-chain logistics, features an integrated amplification system, and delivers lab-quality results directly at the point of care to facilitate immediate clinical decisions. The test is authorized for prescription home use, making it the first U.S. Food and Drug Administration (FDA)-cleared molecular diagnostic test for multiple sexually transmitted infections (STIs) that can be utilized outside clinical environments. This launch indicates a move towards decentralized diagnostic options that improve access, especially in underserved or remote areas.

Which Key Market Players Are Investing In Expansion And Innovation Of Molecular Diagnostics For Sexually Transmitted Diseases Market?

Major companies operating in the molecular diagnostics for sexually transmitted diseases market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Hologic Inc., bioMérieux S.A., QuidelOrtho Corporation, QIAGEN N.V., Cepheid, Sansure Biotech Inc., OraSure Technologies Inc., Meridian Bioscience, Seegene Inc., Visby Medical Inc., Zeesan Biotech, Binx Health Inc., GCC Biotech, GeneProof, and Solone Life Sciences India (P) Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-for-sexually-transmitted-diseases-global-market-report

What Are The Regional Market Dynamics Impacting The Molecular Diagnostics For Sexually Transmitted Diseases Industry?

North America was the largest region in the molecular diagnostics for sexually transmitted diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molecular diagnostics for sexually transmitted diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Molecular Diagnostics For Sexually Transmitted Diseases Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27351&type=smp

Browse Through More Reports Similar to the Global Molecular Diagnostics For Sexually Transmitted Diseases Market 2025, By The Business Research Company

Personal Loans Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/personal-loans-global-market-report

Trade Credit Insurance Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/trade-credit-insurance-global-market-report

Household Insecticides Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/household-insecticides-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Molecular Diagnostics For Sexually Transmitted Diseases Industry?

The market size for molecular diagnostics used for sexually transmitted diseases has experienced a speedy growth recently. It is predicted to rise from $3.31 billion in 2024 to $3.67 billion by 2025, suggesting a compound annual growth rate (CAGR) of 10.9%. Factors like increased instances of sexually transmitted infections, the rising application of nucleic acid amplification tests, growing cognizance through government instituted screening programs, assistance from worldwide health organizations, and swift adoption in diagnostic laboratories have contributed to the expansion observed in the historic period.

The demand for molecular diagnostics in the marketplace for sexually transmitted diseases is predicted to experience significant expansion in the coming years. The market size is projected to reach $5.48 billion by 2029, propelled by a compound annual growth rate (CAGR) of 10.5%. The projected surge during the forecast period can be linked to an emphasis on early detection of diseases, surging demand for individualized diagnostics, the growth of sexually transmitted infection monitoring programs, the proliferation of public-private partnerships, and an escalating preference for non-invasive testing methods. The forecast period will also witness technological advancements in the field of molecular assay platforms, point-of-care diagnostic device innovation, the evolution of multiplex polymerase chain reaction (PCR)-based testing panels, in-depth research and improvement of portable and automated systems, as well as the adoption of artificial intelligence in result interpretation.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27351&type=smp

What Forces Are Driving The Growth Of The Molecular Diagnostics For Sexually Transmitted Diseases Industry?

An upward trend in sexually transmitted infections (STIs) is anticipated to fuel the expansion of the molecular diagnostics market for sexually transmitted diseases. STIs, infections transmitted primarily through sexual activity, can be caused by bacteria, viruses, or parasites and can affect the urinary and reproductive systems. The rising incidence of STIs is largely attributed to inconsistent use of protective methods, elevating the risk of transmitting infections among sexually active people. The crucial role of molecular diagnostics in the management of STIs cannot be understated. It allows for earlier and more precise pathogen detection – even in asymptomatic individuals. This leads to punctual treatment, minimized transmission of the disease, and improved patient outcomes overall. For example, The National Association of County and City Health Officials (NACCHO), a US nonprofit organization, reported a total of 3,755 congenital syphilis cases in January 2024, marking a 31% increase between 2021 and 2022. Hence, the expanding prevalence of STIs is contributing to the growth of the molecular diagnostics market for sexually transmitted diseases.

What Is The Overview Of Market Segmentation In The Molecular Diagnostics For Sexually Transmitted Diseases Industry?

The molecular diagnostics for sexually transmitted diseases market covered in this report is segmented

1) By Product: Instruments And Services, Consumables, Software

2) By Technology: Laboratory Testing, Point-Of-Care Testing

3) By Application: Chlamydia Trachomatis (CT) Or Neisseria Gonorrhoeae (NG) Testing, Syphilis Testing, Gonorrhea Testing, Herpes Simplex Virus (HSV) Testing, Human Papillomavirus (HPV) Testing, Human Immunodeficiency Virus (HIV) Testing, Trichomonas, Ureaplasma And Mycoplasma, Other Applications

Subsegment:

1) By Instruments And Services: Molecular Diagnostic Analyzers, Automated Polymerase Chain Reaction Systems, Nucleic Acid Extraction Instruments, Diagnostic Service Providers, Maintenance And Calibration Services, Installation And Training Services

2) By Consumables: Deoxyribonucleic Acid Extraction Kits, Ribonucleic Acid Extraction Kits, Polymerase Chain Reaction Reagents, Nucleic Acid Probes, Control And Reference Standards, Detection Enzymes And Buffers

3) By Software: Data Interpretation And Reporting Software, Polymerase Chain Reaction Workflow Management Software, Laboratory Information Management Systems, Diagnostic Decision Support Software, Quality Control Monitoring Software

What Future Market Trends Are Projected For The Molecular Diagnostics For Sexually Transmitted Diseases Industry?

Leading firms in the sexually transmitted diseases molecular diagnostics market are primarily concentrating on the creation of innovative solutions, including quick point-of-care polymerase chain reaction (PCR) devices, to augment diagnostic speed, precision, and approachability. Quick point-of-care polymerase chain reaction (PCR) devices are mobile molecular diagnostic instruments that integrates the preparation, amplification, and detection of a sample into a single, convenient unit, thereby enabling swift and highly sensitive pathogen identification beyond traditional laboratory environments. For instance, in March 2025, Visby Medical, a diagnostic technology firm based in the US, introduced the Visby Medical Women’s Sexual Health Test. This product is a single-use, portable PCR device built to detect chlamydia, gonorrhea, and trichomoniasis from vaginal samples in under 30 minutes. It functions without external instruments or cold-chain logistics, has a built-in amplification system, and provides lab-grade results right at the point of care to aid instant clinical decisions. The test has been authorized for prescription home use, making it the first molecular diagnostic test for multiple sexually transmitted infections (STIs) approved by the U.S. Food and Drug Administration (FDA) for use outside of clinical settings. This release signifies a transition towards decentralized diagnostic solutions that expand accessibility, majorly among underserved or distant populations.

Who Are The Primary Players Operating Across The Global Molecular Diagnostics For Sexually Transmitted Diseases Market?

Major companies operating in the molecular diagnostics for sexually transmitted diseases market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Hologic Inc., bioMérieux S.A., QuidelOrtho Corporation, QIAGEN N.V., Cepheid, Sansure Biotech Inc., OraSure Technologies Inc., Meridian Bioscience, Seegene Inc., Visby Medical Inc., Zeesan Biotech, Binx Health Inc., GCC Biotech, GeneProof, and Solone Life Sciences India (P) Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-for-sexually-transmitted-diseases-global-market-report

Which Region Offers The Most Growth Potential For The Molecular Diagnostics For Sexually Transmitted Diseases Market Through 2029?

North America was the largest region in the molecular diagnostics for sexually transmitted diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molecular diagnostics for sexually transmitted diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=27351&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model